Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Simple scope procedure may prevent radiation damage in recurrent nose cancer

NCT ID NCT07552883

Prevention Sponsor: Jiangxi Provincial Cancer Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether removing a thin layer of tissue (pseudomembrane) from the back of the nose using a scope can prevent radiation-induced tissue death in patients with recurrent nasopharyngeal cancer who have had repeat radiation. About 40 adults in China will undergo the procedure. The goal is to cut the 2-year risk of tissue death from the expected 40% down to 20%.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Endoscopic nasopharyngeal pseudomembrane removal
What this could lead to
If it works, this simple procedure could significantly lower the risk of severe nasal tissue damage after repeat radiation for recurrent nasopharyngeal cancer.
What could go wrong
This is a small, early-stage study with only 40 participants and no comparison group, so results may not be definitive. The procedure itself carries risks like bleeding or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Apr 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Voluntarily sign the informed consent form. * Age between 18 and 80 years. * ECOG performance status ≤ 2. * Prior radical radiotherapy with total dose ≥ 66 Gy. * Imaging or histopathology confirmed local recurrence and/or retropharyngeal lymph node recurrence, with or without cervical lymph node recurrence. * Re-irradiation with single dose \< 2.3 Gy and total dose ≥ 50 Gy. * Presence of pseudomembrane reaction on nasopharyngeal mucosa during or after re-irradiation. * Expected survival \> 1 year. * Induction chemotherapy, immunotherapy, concurrent chemotherapy, adjuvant chemotherapy, or radiotherapy alone are all permitted. Exclusion Criteria: * History of other malignancies within the past 5 years, except cured non-melanoma skin cancer or carcinoma in situ of the cervix. * Severe uncontrolled systemic diseases (e.g., uncontrolled infection, severe cardiovascular disease, uncontrolled diabetes). * Pregnant or breastfeeding women. * Known allergy to any equipment or medication used during endoscopy. * Inability to tolerate endoscopic procedure due to anatomical or medical reasons. * Concurrent participation in another interventional clinical trial. * Any condition that, in the investigator's judgment, would interfere with study compliance or outcome assessment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Nasopharyngeal carcinoma (NPC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

nasopharyngeal carcinoma Necrosis radiation injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Nasopharyngeal carcinoma (NPC) Necrosis Radiation injuries

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.